The ACE Center Presents: ACE Center Webinar: Anti-GD2 immunotherapy: A Game Changer in High-Risk Neuroblastoma Join Kristen Dalton and Linda D’Angela, for this live webinar delves into the advanced use of anti-GD2 immunotherapies in the treatment of high-risk neuroblastoma. Participants will explore the purpose and pathophysiology of these therapies, supported by current literature. The session will distinguish between Dinutuximab and Naxitamab, focusing on their administration, timelines, and adverse event management. Additionally, nursing implications for patients receiving anti-GD2 therapies will be discussed, along with recent advances in administration and management, including institutional pathways, open protocols, and future directions. Finally, the coordination…